Estrella Immunopharma, Inc. (ESLA)
NASDAQ
Closed
Oct 8, 2026
Day's Range
0.361152 wk Range
0.3611Overview - ESLA - Estrella Immunopharma, Inc.
Key Statistics
Valuation
Enterprise Value
20.77M
P/E (Trailing)
‪-1.33‬
P/E (Forward)
‪-1.50‬
PEG Ratio
‪0.02‬
Price / Book
‪-2.70‬
EV / EBITDA
‪-1.59‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-251.86%‬
Return on Equity
‪126.02%‬
Ownership
Shares Outstanding
43.03M
Float
14.37M
Short % of Shares Outstanding
‪0.88%‬
Held by Insiders
‪60.42%‬
Held by Institutions
‪11.13%‬
Price stats
Beta
‪0.88‬
50-Day Avg
‪0.6939‬
200-Day Avg
‪1.12‬
Dividends
Payout Ratio
‪0.00%‬
Shariah Compliance
Report Date: Feb 15, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ESLA - Estrella Immunopharma, Inc.
Peers - ESLA - Estrella Immunopharma, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ESLANASDAQEstrella Immunopharma, Inc.20.92MMarket Cap-147.40%52-week change-1.34P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE57.50BMarket Cap+14.28%52-week change34.96P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.40BMarket Cap-105.72%52-week change38.35P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.34BMarket Cap-8.52%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.99BMarket Cap+7.48%52-week change17.72P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.14BMarket Cap+18.80%52-week change-17.80P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - ESLA - Estrella Immunopharma, Inc.
About
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing T-cell therapies for blood cancers, solid tumors, and certain autoimmune diseases. The company is centered on CD19- and CD22-targeted ARTEMIS T-cell programs designed to harness the immune system’s ability to recognize and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
